SCHEMBL3733678

SCHEMBL3733678

CC(=O)NC1CCNC1=O

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 14/20 0.51
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12285520 1.00 CCR2 (0.51) CCR2RAB9ANPC1
SCHEMBL12332205 1.00 CCR2 (0.51) CCR2RAB9ANPC1
SCHEMBL4074292 0.89 CCR2 (0.61) CCR2RAB9ANPC1
SCHEMBL4087770 0.89 CCR2 (0.61) CCR2RAB9ANPC1
SCHEMBL4074289 0.89 CCR2 (0.61) CCR2RAB9ANPC1
SCHEMBL8317734 0.87 CCR2 (0.69) CCR2RAB9ANPC1
SCHEMBL3954242 0.87 CCR2 (0.69) CCR2RAB9ANPC1
SCHEMBL14778920 0.82 CCR2 (0.50) CCR2RAB9ANPC1
SCHEMBL3936733 0.82 CCR2 (0.50) CCR2RAB9ANPC1
SCHEMBL7383773 0.82 CCR2 (0.50) CCR2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
EP-4400497-A1 3CLPRO PROTEASE INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-07-17 EP disclosed
US-20230159584-A1 CLEAVABLE LINKER FOR PEPTIDE SYNTHESIS ROCHE SEQUENCING SOLUTIONS INC (US) 2023-05-25 US disclosed
WO-2023036140-A1 3CLPRO PROTEASE INHIBITOR 上海齐鲁制药研究中心有限公司 2023-03-16 WO disclosed
WO-2020210828-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HIBERCELL, INC. (US) 2020-10-15 WO disclosed
US-20150072993-A1 Parasiticidal Dihydroisoxazole Compounds JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2015-03-12 US disclosed
US-8889710-B2 Parasiticidal dihydroisoxazole compounds ELI LILLY AND COMPANY (US) 2014-11-18 US disclosed
US-20140107149-A1 PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS ELI LILLY AND COMPANY (US) 2014-04-17 US disclosed
US-8648081-B2 Parasiticidal dihydroisoxazole compounds ELI LILLY AND COMPANY (US) 2014-02-11 US disclosed
US-20130217699-A1 PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-08-22 US disclosed
US-8242285-B2 N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
WO-2011109657-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS SATORI PHARMACEUTICALS, INC. (US) 2011-09-09 WO disclosed
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 US disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 US disclosed
CN-101415676-A N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same SUMITOMO CHEMICAL CO (JP) 2009-04-22 CN disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 EP disclosed
EP-0131839-B1 QUINOLINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1989-02-01 EP disclosed
EP-0153580-A1 Naphthyridine antibacterial compounds ABBOTT LABORATORIES (US) 1985-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159584-A1 CLEAVABLE LINKER FOR PEPTIDE SYNTHESIS VIP, DNPEP, SPPL2B CCR2 2627/4885RAB9A 4487/4885NPC1 4284/4885
US-20140107149-A1 PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS DHODH, DDT, CYP51A1 CCR2 3441/4885RAB9A 689/4885NPC1 994/4885
US-20130217699-A1 PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS DHODH, DDT, CYP51A1 CCR2 3559/4885RAB9A 736/4885NPC1 1094/4885
US-20150072993-A1 Parasiticidal Dihydroisoxazole Compounds DHODH, DDT, CYP51A1 CCR2 3441/4885RAB9A 689/4885NPC1 994/4885
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 CCR2 233/4885RAB9A 2480/4885NPC1 2992/4885
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof TERT, CBR1, TELO2 CCR2 233/4885RAB9A 2480/4885NPC1 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.